Literature DB >> 3580026

Bioavailability of controlled-release metoclopramide. 1st communication: single dose study.

A H Beckett, W A Behrendt, B W Hadzija.   

Abstract

The bioavailability of metoclopramide monochloride hydrate after single dose oral administration of a controlled-release capsule (Gastro-Timelets) was compared with that of oral metoclopramide monochloride hydrate solution in four normal volunteers. 30 mg of each product was administered to each subject in a cross-over manner on two separate occasions and plasma metoclopramide levels were measured using a HPLC method. Although peak plasma metoclopramide concentrations were lower, and occurred later after capsule treatment than after solution, analysis of the area under the plasma concentration-time curve (AUC) values for the two formulations demonstrated that the products were equivalent in terms of the extent of absorption, with the mean AUC value (0-30 h) for the capsule 943.7 ng/h/ml and that for the solution 896.2 ng/h/ml.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3580026

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

Review 1.  Pharmacokinetic optimisation of antiemetic therapy.

Authors:  M Campbell; D N Bateman
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

2.  Comparison of the pharmacokinetics of a new 30 mg modified-release tablet formulation of metoclopramide for once-a-day administration versus 10 mg immediate-release tablets: a single and multiple-dose, randomized, open-label, parallel study in healthy male subjects.

Authors:  Roberto Bernardo-Escudero; Rosalba Alonso-Campero; María Teresa de Jesús Francisco-Doce; Myriam Cortés-Fuentes; Miriam Villa-Vargas; Juan Angeles-Uribe
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-02-11       Impact factor: 2.441

3.  Preparation and comparative evaluation of sustained release metoclopramide hydrochloride matrix tablets.

Authors:  Sayed I Abdel-Rahman; Gamal M Mahrous; Mahmoud El-Badry
Journal:  Saudi Pharm J       Date:  2009-11-10       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.